Abstracts tagged "myopathy and polymyositis/dermatomyositis (PM/DM)"

Abstract Number: 282 • 2016 ACR/ARHP Annual Meeting
From ‘immune Mediated Necrotizing Myopathy’ to ‘antibody-Mediated Necrotizing Myositis: Towards the Pathogenic Role of Anti-SRP and Anti-Hmgcr Antibodies’
Yves Allenbach¹, Louiza Arouche-Delaperche², Corinna Preusse³, Gillian Butler Browne², Nicolas Champtiaux⁴, Kuberaka Mariampillai⁵, Aude Rigolet⁶, Peter Hufnagl⁷, Norman Zerbe⁸, Thierry Maisonobe⁹, Damien Amelin², Sarah Leonard-louis¹⁰, Charles Duyckaerts¹¹, Bruno Eymard¹², Hans-Hilmar Goebel³, Laurent Drouot¹³, Olivier Boyer¹⁴, Olivier Benveniste^2,5 and Werner Stenzel³, ¹Pitié-Salpêtrière University Hospital, AP-HP, Department of Internal Medicine and Clinical Immunology, Paris, France, Paris, France, ²Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ³Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ⁴Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁵Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ⁶Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁷Pathology departmen, Charite Hospital, Berlin, Germany, ⁸Department of Pathology, Charite Hospital, Berlin, Germany, ⁹Pitié-Salpêtrière University Hospital, AP-HP, Department of Neuropathology, Paris, France, Paris, France, ¹⁰Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Neuropathology, Paris, France, Paris, France, ¹¹Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ¹²Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ¹³Immunology, INSERM U905, University of Rouen, Rouen, France, ¹⁴Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Immune mediated necrotizing myopathy (IMNM) has been recently added as a new entity among dermatomyositis, polymyositis and sporadic inclusion body myositis. IMNM is defined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].